Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTL0009936 in healthy elderly subjects
NCT02546310Phase 1Completed
- Sponsor
- Nxera Pharma
- Start
- Oct 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HTL0009936 in Alzheimer's disease (AD) (3 arms), sponsored by Nxera Pharma. Primary endpoint: Blood oxygen level dependent signal in fMRI at Day 1. Started Oct 2015; status: completed.
02
Drugs
HTL0009936
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02546310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546310.